 The Phase 12 multicenter study to assess the safety, tolerability and efficacy of MB-106 in patients with relapsed or refractory CD20 B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia is expected to begin enrolling patients in the third quarter of this year 